Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1506 • ACR Convergence 2021
SLAMF6 Compartmentalization Regulates Autoimmune T Cell Responses
Yevgeniya Gartshteyn¹, Anca Askanase² and Adam Mor³, ¹Columbia University Medical Center, Glen Rock, NJ, ²Columbia University Medical Center, New York, NY, ³CUIMC, New York, NY
Background/Purpose: T cell activation is initiated by engagement of the T cell receptor (TCR) complex and requires co-receptor signaling. SLAMF6 is a major T cell…
Abstract Number: 1718 • ACR Convergence 2021
Use of Gonadotropin Releasing Hormone Agonist for Ovarian Preservation in SLE Patients on Cyclophosphamide
Jun Chu¹, Alice Fike², Michael Davis³, Zerai Manna⁴, Komal Ejaz⁵, Yenealem Temesgen-Oyelakin⁶, Elaine Poncio⁷, Isabel Ochoa⁷, Alan Decherney⁴ and Sarfaraz Hasni⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ³NIAMS, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Sheikh Zayed Medical College, Scranton, PA, ⁶National Institutes of Health (NIH), Bethesda, MD, ⁷NIH/NIAMS, Bethesda, MD
Background/Purpose: SLE is an autoimmune disease which predominantly affects women of childbearing age (age 20-40). Most of the medications used for treating SLE can adversely…
Abstract Number: 1746 • ACR Convergence 2021
Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial
Thomas Dörner¹, Ronald Van Vollenhaven², Andrea Doria³, Bochao Jia⁴, Damiano Fantini⁴, Jorge Ross Terres⁴, Maria Silk⁵, Stephanie de Bono⁴, Peter Fischer⁶ and Daniel Wallace⁷, ¹Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ²University Medical Center, Amsterdam, Netherlands, ³University of Padova, Padova, Italy, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Carmel, IN, ⁶Eli Lilly and Company, North Easton, MA, ⁷Cedars-Sinai, Los Angeles, CA
Background/Purpose: Baricitinib (BARI), an oral, selective Janus kinase (JAK)1 and JAK2 inhibitor, improved disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background…
Abstract Number: 1765 • ACR Convergence 2021
Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG A and/or Two BILAG B Domain Scores?
Ewa Olech¹, Faizi Hussain² and Joan Merrill³, ¹IQVIA, Las Vegas, NV, ²IQVIA, Redding, United Kingdom, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…
Abstract Number: 1936 • ACR Convergence 2021
A Neutrophil Degranulation Signature Identifies Proliferative Lupus Nephritis
Andrea Fava¹, Jessica Li¹, Daniel Goldman², Brendan Antiochos¹, Jose Monroy-Trujillo¹, Derek Fine¹, Mohamed G. Atta¹, Jill Buyon³, Joel Guthridge⁴, Judith James⁴, Michelle Petri² and Accelerating Medicines Partership (AMP) RA/SLE Network⁵, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NYU School of Medicine, New York, NY, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Brigham and Women's Hospital, Everett, MA
Background/Purpose: The identification of intrarenal pathological processes is key to develop better diagnostic and treatment strategies in lupus nephritis (LN). But the direct comprehensive study…
Abstract Number: 0083 • ACR Convergence 2021
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Tali Eviatar¹, Stanley Niznik², Nancy Agmon-Levin² and Daphna Paran³, ¹Tel Aviv Sourasky Medical Center, Givataim, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…
Abstract Number: 0325 • ACR Convergence 2021
A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus
Roberta Alexander¹, Scott Rey¹, John Conklin¹, Vinicius Domingues², Mansoor Ahmed³, Jazibeh Qureshi⁴ and Arthur Weinstein⁵, ¹Exagen Inc., Vista, CA, ²Florida State university, Daytona beach, FL, ³Arthritis Osteo Ctr of KY, Richmond, KY, ⁴Rheumatology Express, Catonsville, MD, ⁵Loma Linda University (Voluntary Position), Claremont, CA
Background/Purpose: The multianalyte assay panel (MAP) consists of cell-bound complement activation products (CB-CAPs) with lupus and non-lupus autoantibodies combined in an algorithm (Dervieux et al.,…
Abstract Number: 0341 • ACR Convergence 2021
Addition of Narrative Text Abstraction to ICD-Based Abstraction Significantly Improves Identification of Lupus Nephritis in Real-World Data
Meghan Tierney and Chris Rowe, PicnicHealth, San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is often underrecognized and difficult to identify retrospectively, presenting challenges for clinicians and researchers hoping to explore this condition using real-world…
Abstract Number: 0472 • ACR Convergence 2021
An Atlas of Human and Mouse Intrarenal Immune Cells in Lupus Nephritis Reveals Homologous Immune Populations Across Common Mouse Strains and Species
Paul Hoover¹, Michael Peters², David Lieb², Runci Wang³, Garett Dunlap⁴, Deepak Rao¹, Nir Hacohen² and Anne Davidson⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Harvard University, Somerville, MA, ⁵Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We discovered 21 immune cell-types in lupus nephritis kidney biopsies as part of the Accelerating Medicines Partnership (AMP) consortium. These immune cells are the…
Abstract Number: 0598 • ACR Convergence 2021
Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study
Adrienne Joseph, Brandon Windsor, Linda Hynan and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Epidemiological studies have shown that discoid lupus erythematosus (DLE) has a higher incidence and prevalence in minorities, particularly Black individuals. Racial differences in clinical…
Abstract Number: 0770 • ACR Convergence 2021
Evaluation of the Lupus Low Disease Activity State (LLDAS) vs. the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K Score in a Pediatric Systemic Lupus Erythematosus Cohort
Bridget Wilson, Tingting Qiu, Angela Merritt, Bin Huang and Hermine Brunner, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease which can affect any organ system, and ongoing disease activity leads to organ damage. The…
Abstract Number: 0866 • ACR Convergence 2021
Characteristics Associated with Poor COVID-19 Outcomes in People with Systemic Lupus Erythematosus (SLE): Data from the COVID-19 Global Rheumatology Alliance (GRA)
Manuel Ugarte-Gil¹, Graciela Alarcn², Andrea Seet³, Zara Izadi³, Ali Duarte-Garcia⁴, Cristina Reategui-Sokolova⁵, Ann Clarke⁶, Leanna Wise⁷, Guillermo Pons-Estel⁸, Maria José Santos⁹, Sasha Bernatsky¹⁰, Sandra Lúcia Ribeiro¹¹, Samar Al Emadi¹², Jeffrey Sparks¹³, Tiffany Hsu¹⁴, Kristin D'Silva¹⁵, Naomi Patel¹⁵, Emily Gilbert¹⁶, Maria Valenzuela-Almada¹⁷, Andreas Jnsen¹⁸, Gianpiero Landolfi¹⁹, Micaela Fredi²⁰, Tiphaine Goulenok²¹, Mathilde Devaux²², Xavier Mariette²³, Viviane Queyrel²⁴, Vasco C Romão²⁵, Graça Sequeira²⁶, Rebecca Hasseli²⁷, Bimba Franziska Hoyer²⁸, Reinhard Voll²⁹, Christof Specker³⁰, Roberto Baez³¹, Vanessa Castro Coello³², Edgard Neto³³, Gilda Ferreira³⁴, Odirlei Andre Monticielo³⁵, Emily Sirotich³⁶, Jean Liew³⁷, Jonathan Hausmann³⁸, Paul Sufka³⁹, Rebecca Grainger⁴⁰, Suleman Bhana⁴¹, Wendy Costello⁴², Zachary Wallace⁴³, Lindsay Jacobsohn⁴⁴, Anja Strangfeld⁴⁵, Elsa Frazão Mateus⁴⁶, Kimme Hyrich⁴⁷, Laure Gossec⁴⁸, Loreto Carmona¹, Saskia Lawson-Tovey⁴⁷, Lianne Kearsley-Fleet⁴⁹, Martin Schaefer⁵⁰, Pedro Machado⁵¹, Philip Robinson⁵², Milena Gianfrancesco³ and Jinoos Yazdany³, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²University of Alabama at Birmingham, Birmingham, AL, ³University of California San Francisco, San Francisco, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁶University of Calgary, Calgary, AB, Canada, ⁷LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁸Centro Regional de Enfermedades Autoinmunes y Reumaticas (CREAR), Rosario, Argentina, ⁹Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰McGill University, Montréal, QC, Canada, ¹¹Universidade Federal do Amazonas, Amazonas, Brazil, ¹²Hamad medical corporation, Doha, Qatar, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴Brigham and Women's Hospital, Jamaica Plain, MA, ¹⁵Massachusetts General Hospital, Boston, MA, ¹⁶Mayo Clinic, Jacksonville, FL, ¹⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁸Lund University, Lund, Sweden, ¹⁹Epidemiology Research Unit, Italian Society for Rheumatology, Milan, Italy, ²⁰Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²¹Internal Medicine Department, Bichat Claude Bernard Hospital, Paris, France, ²²Service de Médecine Interne, CHI Poissy Saint Germain, Poissy, France, ²³Université Paris- Saclay, Rheumatology, Paris, France, ²⁴University Hospital of Nice, Nice, France, ²⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ²⁶Centro Hospitalar Universitário do Algarve, Unidade de Faro, Faro, Portugal, ²⁷Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, ²⁸Universittsklinikum Schleswig-Holstein, Kiel, Germany, ²⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ³⁰Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ³¹Hospital Francisco Lopez Lima, General Roca, Rio Negro, Argentina, ³²Sanatorio Güemes, Buenos Aires, Argentina, ³³UNIFESP, São Paulo, Brazil, ³⁴Federal University of Minas Gerais, Belo Horizonte, Brazil, ³⁵Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³⁶McMaster University, Hamilton, ON, Canada, ³⁷Boston University, Boston, MA, ³⁸Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ³⁹HealthPartners, Eagan, MN, ⁴⁰University of Otago, Wellington, New Zealand, ⁴¹Crystal Run Health, Montvale, NJ, ⁴²Irish Children's Arthritis Network, Bansha, Ireland, ⁴³Massachusetts General Hospital, Newton, MA, ⁴⁴University of California San Francisco, Antioch, CA, ⁴⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁴⁶Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ⁴⁷University of Manchester, Manchester, United Kingdom, ⁴⁸Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ⁴⁹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁵⁰German Rheumatism Research Center, Berlin, Germany, ⁵¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁵²Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Preliminary data in people with SLE suggested that disease activity as well as SLE treatment at time of COVID-19 acquisition impact COVID-19 outcomes over…
Abstract Number: 0882 • ACR Convergence 2021
COVID-19 Impact Among Patients with Systemic Lupus Erythematosus
Jose Rubio¹, Suzanne krishfield¹ and Vasileios Kyttaris², ¹Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ²BIDMC, Boston, MA
Background/Purpose: Initial studies of SLE patients with COVID-19 revealed an increased risk for severe disease in people with distinct demographic features such as advanced age…
Abstract Number: 0970 • ACR Convergence 2021
Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes
Grace Hile¹, Patrick Coit², Bin Xu¹, Shannon Estadt¹, Jacob Martens³, Rachael Wasikowski¹, Lam Tsoi¹, Ramiro Iglesias-Bartolome⁴, Celine Berthier¹, Allison Billi⁵, Johann Gudjonsson⁵, Amr Sawalha² and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA, ³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁴NIH, National Cancer Institute, Bethesda, MD, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation and photosensitivity are common manifestations of cutaneous (CLE) and systemic lupus erythematosus (SLE), yet the mechanisms underlying heightened cell death and epidermal…
Abstract Number: 1056 • ACR Convergence 2021
Characterization of the Patterns of Care, Access and Direct Costs of Systemic Lupus Erythematosus in Brazil: Findings from the Macunaíma Study
Mirhelen Mendes de Abreu¹, Vander Fernandes², Odirlei Andre Monticielo³, Alexandre Cristovão Maiorano¹, Fernando dos Santos Beserra¹, Flavia Rachel Moreira Lamarão⁴, Nathalie David⁴, Bruna de Veras⁴, Magda Araujo⁴, Blanca Elena Rios Gomes Bica⁵, Dalianna Luise Andrade Souto Rodrigues², Guilherme Andrade Bulbol⁶, Natalia Jardim Martins da Silva⁷, Domingos Sávio Nunes de Lima⁶ and Marta Maria das Chagas Medeiros⁷, ¹Faculdade de Medicina, Universidade Federal do Rio de Janeiro; MAPEAR Laboratory, Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, ²Universidade de Cuiabá, Cuiabá, Brazil, ³Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁴GlaxoSmithKline, Medical Department, Rio de Janeiro, Brazil, ⁵Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Hospital Universitário Getúlio Vargas, Universidade Federal do Amazonas, Manaus, Brazil, ⁷Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, Brazil
Background/Purpose: This study evaluated the patterns of care, access and direct costs related to the management and treatment of patients with systemic lupus erythematosus (SLE)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].